BIOMERICA INC (BMRA) Stock Price, Forecast & Analysis
USA - NASDAQ:BMRA - US09061H4065 - Common Stock
BMRA Key Statistics, Chart & Performance
The current stock price of BMRA is 2.46 USD. In the past month the price decreased by -13.07%. In the past year, price decreased by -21.15%.
BMRA Latest News, Press Relases and Analysis
BMRA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.32 | 219.92B | ||
| ISRG | INTUITIVE SURGICAL INC | 65.04 | 200.75B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.91 | 148.20B | ||
| SYK | STRYKER CORP | 27.03 | 136.11B | ||
| IDXX | IDEXX LABORATORIES INC | 56.18 | 56.68B | ||
| BDX | BECTON DICKINSON AND CO | 12.33 | 50.97B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.45 | 48.96B | ||
| RMD | RESMED INC | 25.4 | 36.70B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.92 | 33.35B | ||
| PODD | INSULET CORP | 75.61 | 22.51B | ||
| DXCM | DEXCOM INC | 29.57 | 21.57B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.94 | 17.53B |
Related stock screener links
About BMRA
Company Profile
Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company is headquartered in Irvine, California and currently employs 53 full-time employees. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. The company is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.
Company Info
BIOMERICA INC
17571 Von Karman Avenue
Irvine CALIFORNIA 92614 US
CEO: Zackary S. Irani
Employees: 64
Phone: 19493792875
BIOMERICA INC / BMRA FAQ
What does BMRA do?
Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company is headquartered in Irvine, California and currently employs 53 full-time employees. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. The company is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.
What is the stock price of BIOMERICA INC today?
The current stock price of BMRA is 2.46 USD. The price decreased by -3.53% in the last trading session.
What is the dividend status of BIOMERICA INC?
BMRA does not pay a dividend.
What is the ChartMill rating of BIOMERICA INC stock?
BMRA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is BIOMERICA INC worth?
BIOMERICA INC (BMRA) has a market capitalization of 7.06M USD. This makes BMRA a Nano Cap stock.
BMRA Technical Analysis
BMRA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BMRA. BMRA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
BMRA Financial Highlights
Over the last trailing twelve months BMRA reported a non-GAAP Earnings per Share(EPS) of -2.25. The EPS increased by 20.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -83.65% | ||
| ROE | -121.14% | ||
| Debt/Equity | 0 |